Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emanuel Raschi

Showing results (1-10 of 213) with videos related to

Pageof 22
Sort By:
JAMA Network Open|November 22, 2022
Interstitial Lung Disease With Non-Vitamin K Oral Anticoagulants-A Clinical Concern?Emanuel Raschi
Hepatology (Baltimore, Md.)|February 27, 2022
Letter to the editor: RECAM for the diagnosis of DILI-Is it time to incorporate additional pharmacological criteria?Emanuel Raschi, Paolo Caraceni
The New England Journal of Medicine|April 16, 2025
Abelacimab versus Rivaroxaban in Patients with Atrial FibrillationEmanuel Raschi, Alessandro Squizzato
Heart (British Cardiac Society)|November 29, 2017
Liver injury with direct-acting anticoagulants: has the fog cleared?Emanuel Raschi, Fabrizio De Ponti
World Journal of Hepatology|July 14, 2015
Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing riskEmanuel Raschi, Fabrizio De Ponti
Expert Opinion on Drug Metabolism & Toxicology|January 7, 2014
Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndromeEmanuel Raschi, Fabrizio De Ponti
Internal and Emergency Medicine|December 14, 2011
Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncologyEmanuel Raschi, Fabrizio De Ponti
Frontiers in Pharmacology|November 12, 2019
Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 InhibitorsEmanuel Raschi, Fabrizio De Ponti
World Journal of Hepatology|January 21, 2017
Drug-induced liver injury: Towards early prediction and risk stratificationEmanuel Raschi, Fabrizio De Ponti
JAMA Internal Medicine|October 30, 2013
Glucagon-like peptide 1-based drugs and pancreatic safetyEmanuel Raschi, Carlo Piccinni, Giulio Marchesini
Pageof 22

Showing results (1-10 of 213) with videos related to

Sort By:
Pageof 22
JAMA Network Open|November 22, 2022
Interstitial Lung Disease With Non-Vitamin K Oral Anticoagulants-A Clinical Concern?Emanuel Raschi
Hepatology (Baltimore, Md.)|February 27, 2022
Letter to the editor: RECAM for the diagnosis of DILI-Is it time to incorporate additional pharmacological criteria?Emanuel Raschi, Paolo Caraceni
The New England Journal of Medicine|April 16, 2025
Abelacimab versus Rivaroxaban in Patients with Atrial FibrillationEmanuel Raschi, Alessandro Squizzato
Heart (British Cardiac Society)|November 29, 2017
Liver injury with direct-acting anticoagulants: has the fog cleared?Emanuel Raschi, Fabrizio De Ponti
World Journal of Hepatology|July 14, 2015
Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing riskEmanuel Raschi, Fabrizio De Ponti
Expert Opinion on Drug Metabolism & Toxicology|January 7, 2014
Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndromeEmanuel Raschi, Fabrizio De Ponti
Internal and Emergency Medicine|December 14, 2011
Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncologyEmanuel Raschi, Fabrizio De Ponti
Frontiers in Pharmacology|November 12, 2019
Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 InhibitorsEmanuel Raschi, Fabrizio De Ponti
World Journal of Hepatology|January 21, 2017
Drug-induced liver injury: Towards early prediction and risk stratificationEmanuel Raschi, Fabrizio De Ponti
JAMA Internal Medicine|October 30, 2013
Glucagon-like peptide 1-based drugs and pancreatic safetyEmanuel Raschi, Carlo Piccinni, Giulio Marchesini
Pageof 22